Kirby McInerney LLP Reminds Revance Therapeutics, Inc. (RVNC) Investors of Class Action Filing and Encourages Investors to Contact the Firm

Core Points - A class action lawsuit has been filed against Revance Therapeutics, Inc. for securities fraud, affecting investors who purchased shares between February 29, 2024, and December 6, 2024 [3][4] - The lawsuit alleges that Revance made false or misleading statements and failed to disclose material breaches of a Distribution Agreement, which increased the risk of litigation and potential harm to the company's reputation and finances [4] Company Information - Revance Therapeutics, Inc. is currently facing legal challenges that may impact its stock performance and investor confidence due to allegations of securities fraud [3][4] - Investors have until March 4, 2025, to apply to be appointed as lead plaintiffs in the lawsuit, indicating ongoing legal proceedings that could affect the company's future [3]